DFTX Definium Therapeutics, Inc.
Financings ·
Definium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel.
MindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported.
The company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded.
The amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss.
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing product candidates for brain health disorders, drawn from psychedelic and empathogen drug classes. Its lead candidate, DT120 ODT, is a pharmaceutically optimized form of lysergide D-tartrate in development for generalized anxiety disorder (GAD) and major depressive disorder (MDD). After a Phase 2b trial in GAD met its primary endpoint, the FDA granted breakthrough designation to the DT120 program for GAD in March 2024. Its Phase 3 program for GAD consists of two trials, Voyage and Panorama, and a Phase 3 trial in MDD, Ascend, had sites activated in the first quarter of 2026. Its Voyage trial is expected to report Part A topline results in early third quarter 2026. DT402, also referred to as R(-)-MDMA, is being developed for autism spectrum disorder. The company completed a first clinical trial of DT402 in adult healthy volunteers in October 2024 and initiated a Phase 2a trial in autism spectrum disorder in the fourth quarter of 2025. The company says it applies scientific rigor to psychedelics with the goal of developing accessible treatments for brain health disorders.
| Product or program | What it is | Stage |
|---|---|---|
| DT120 ODT | Lysergide D-tartrate for generalized anxiety disorder and major depressive disorder | Phase 3 |
| DT402 | R(-)-MDMA for autism spectrum disorder | Phase 2a |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $117.7 million | $65.3 million |
| Net income (loss) | -$183.8 million | -$108.7 million |
| Cash from operations | -$131.6 million | -$79.1 million |
| Cash and equivalents | $257.8 million | $273.7 million |
| Short-term investments | $153.8 million | $0 |
Our latest story on this, dated Jun 22, 2026: "Definium launches $500 million offering, then prices 20,588,236 shares at $34.00". The story links the filing or release it is based on. Read the story.
Definium Therapeutics, Inc. trades under the ticker DFTX on NASDAQ.
Definium Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MMQ0; LS:A420P3; LSX:A420P3.
The SEC Central Index Key (CIK) for Definium Therapeutics, Inc. is 1813814. Its filings are on SEC EDGAR.
134,366,950 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Definium Therapeutics, Inc. under United States.
Our directory classifies Definium Therapeutics, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Definium Therapeutics, Inc. is CA24477V1058.
aibio.space lists Definium Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing product candidates for brain health disorders, drawn from psychedelic and empathogen drug classes. Its lead candidate, DT120 ODT, is a pharmaceutically optimized form of lysergide D-tartrate in development for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
DT120 ODT: Lysergide D-tartrate for generalized anxiety disorder and major depressive disorder Stage: Phase 3.
DT402: R(-)-MDMA for autism spectrum disorder Stage: Phase 2a.
Definium Therapeutics, Inc. reported a net loss of $183.8 million for the fiscal year ended Dec 31, 2025, and used $131.6 million of cash in operations, per its annual report to the SEC.
$117.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio